Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 72, Issue 1, Pages 96-118Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.04.040
Keywords
cardiovascular risk; dyslipidemia; nutraceuticals; position paper; statin intolerance
Categories
Funding
- Sanofi
- Valeant
- Amgen
- Angelini
- Boehringer Ingelheim
- Meda
- Merck Sharp Dohme
- AstraZeneca
- KRKA
- Pfizer
- Vifor Pharma
- Bayer
- Brahms
- Chugai Pharma
- Roche
- Novartis
- WinMedica
- Pharma
- Chemistry Competence Center of Latvia
- Libytec
- Aegerion
- Akcea
- Amarin
- Duke
- Esperion
- Eliaz Therapeutics
- FH Foundation
- Gemphire
- Ionis
- Kaneka
- Kastle Therapeutics
- Kowa
- RegenXBio
- Sanofi/Regeneron
- Stage 2 Innovations
- University of Penn
- Zydus Discovery
- Regeneron
- Bristol-Myers Squibb/Pfizer
- Servier
- Abbott
- Actavis
- Genzyme
- SanofiRegeneron
- Eli Lilly
- Meda Pharma
- Novo Nordisk
- Roche Diagnostics
Ask authors/readers for more resources
Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non-lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction. (C) 2018 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available